Literature DB >> 26778002

The modulatory effect of TLR2 on LL-37-induced human mast cells activation.

Yuan-Yuan Zhang1, Yang-Yang Yu2, Ya-Rui Zhang1, Wei Zhang3, Bo Yu4.   

Abstract

The sole and endogenous anti-microbial peptide LL-37 is a significant effector molecule in the innate host defense system. Apart from its broadly direct anti-microbial activity, the peptide also activates mast cell in respect of allergic diseases and inflammation. On the other hand, mast cell can be activated by Toll-like receptors (TLRs) which are at the center of innate immunity. It was the aim of the study to illustrate the modulatory effect of TLR2 ligands peptidoglycan (PGN) and tripalmitoyl-S-glycero-Cys-(Lys)4 (Pam3CSK4) on LL-37 induced LAD2 cells (a human mast cell line) activation. LL-37 induced LAD2 cells degranulation and the release of IL-8. TLR2 ligands didn't induce LAD2 cells degranulation, but triggered the release of IL-8. Incubation with PGN or Pam3CSK4 significantly suppressed LL-37-induced degranulation through inhibition of calcium mobilization from LAD2 cells. Similarly, the release of IL-8 was inhibited when LAD2 cells were co-stimulated with TLR2 ligands and LL-37. Studies with inhibitors of key enzymes involved in mast cell signaling indicated that the release of IL-8 induced by TLR2 ligands and LL-37 involved the activation of the PI3K, ERK, JNK and calcineurin signaling pathways. In contrast, p38 activation down-regulated the release of IL-8 induced by TLR2 ligands and LL-37. Taken together, these observations suggest that activation of human mast cells by LL-37 could be modified by TLR2 ligands and the function of human mast cells could be switched from allergic reactions to innate immune response.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Human mast cells; LL-37; Toll-like receptor 2 (TLR2)

Mesh:

Substances:

Year:  2016        PMID: 26778002     DOI: 10.1016/j.bbrc.2016.01.037

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  P17, an Original Host Defense Peptide from Ant Venom, Promotes Antifungal Activities of Macrophages through the Induction of C-Type Lectin Receptors Dependent on LTB4-Mediated PPARγ Activation.

Authors:  Khaddouj Benmoussa; Hélène Authier; Mélissa Prat; Mohammad AlaEddine; Lise Lefèvre; Mouna Chirine Rahabi; José Bernad; Agnès Aubouy; Elsa Bonnafé; Jérome Leprince; Bernard Pipy; Michel Treilhou; Agnès Coste
Journal:  Front Immunol       Date:  2017-11-30       Impact factor: 7.561

Review 2.  Cathelicidins: Immunomodulatory Antimicrobials.

Authors:  Roel M van Harten; Esther van Woudenbergh; Albert van Dijk; Henk P Haagsman
Journal:  Vaccines (Basel)       Date:  2018-09-14

3.  Host Defense Peptide LL-37-Mediated Chemoattractant Properties, but Not Anti-Inflammatory Cytokine IL-1RA Production, Is Selectively Controlled by Cdc42 Rho GTPase via G Protein-Coupled Receptors and JNK Mitogen-Activated Protein Kinase.

Authors:  Mahadevappa Hemshekhar; Ka-Yee Grace Choi; Neeloffer Mookherjee
Journal:  Front Immunol       Date:  2018-08-13       Impact factor: 7.561

4.  TLR5 is a new reporter for triple-negative breast cancer indicated by radioimmunoimaging and fluorescent staining.

Authors:  Dai Shi; Weiwei Liu; Shanshan Zhao; Chao Zhang; Ting Liang; Guihua Hou
Journal:  J Cell Mol Med       Date:  2019-10-01       Impact factor: 5.310

5.  Design and Immunological Evaluation of a Hybrid Peptide as a Potent TLR2 Agonist by Structure-Based Virtual Screening.

Authors:  Lulu Zhang; Xubiao Wei; Rijun Zhang; Paul E Mozdziak; Dayong Si; Baseer Ahmad; Qiang Cheng; Yucui Tong
Journal:  Front Cell Dev Biol       Date:  2021-02-11

Review 6.  Signal Transduction Pathways Activated by Innate Immunity in Mast Cells: Translating Sensing of Changes into Specific Responses.

Authors:  Zyanya P Espinosa-Riquer; Deisy Segura-Villalobos; Itzel G Ramírez-Moreno; Marian Jesabel Pérez Rodríguez; Mónica Lamas; Claudia Gonzalez-Espinosa
Journal:  Cells       Date:  2020-11-04       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.